Cargando…

Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era

Migraine is a chronic and often lifelong disease that directly affects over one billion people globally. Because access to migraine medical services is limited, only a minority of migraine patients are treated adequately. This situation worsened during the COVID-19 pandemic. Digital therapeutics (DT...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xingchen, Luo, Yujia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842514/
https://www.ncbi.nlm.nih.gov/pubmed/36660558
http://dx.doi.org/10.2147/JPR.S387548
_version_ 1784870145853751296
author Chen, Xingchen
Luo, Yujia
author_facet Chen, Xingchen
Luo, Yujia
author_sort Chen, Xingchen
collection PubMed
description Migraine is a chronic and often lifelong disease that directly affects over one billion people globally. Because access to migraine medical services is limited, only a minority of migraine patients are treated adequately. This situation worsened during the COVID-19 pandemic. Digital therapeutics (DTx) is an emerging therapeutic approach that opens up many new possibilities for remote migraine management. For instance, migraine management tools, online migraine diagnosis, guideline-based treatment options, digitally networked patients, and collecting anonymized information about migraine attacks and course parameters for scientific evaluation. Various applications of DTx in migraine management have been studied in recent years, such as the usefulness of digital migraine self-management tools in diagnosing and tracking migraine attacks, and the efficacy and safety of digital cognitive behavioural therapy. However, the development of DTx is still in its infancy and still faces many obstacles. The primary goal of this study is to review the latest research on DTx in migraine management, identify challenges, and outline future trends.
format Online
Article
Text
id pubmed-9842514
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98425142023-01-18 Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era Chen, Xingchen Luo, Yujia J Pain Res Review Migraine is a chronic and often lifelong disease that directly affects over one billion people globally. Because access to migraine medical services is limited, only a minority of migraine patients are treated adequately. This situation worsened during the COVID-19 pandemic. Digital therapeutics (DTx) is an emerging therapeutic approach that opens up many new possibilities for remote migraine management. For instance, migraine management tools, online migraine diagnosis, guideline-based treatment options, digitally networked patients, and collecting anonymized information about migraine attacks and course parameters for scientific evaluation. Various applications of DTx in migraine management have been studied in recent years, such as the usefulness of digital migraine self-management tools in diagnosing and tracking migraine attacks, and the efficacy and safety of digital cognitive behavioural therapy. However, the development of DTx is still in its infancy and still faces many obstacles. The primary goal of this study is to review the latest research on DTx in migraine management, identify challenges, and outline future trends. Dove 2023-01-12 /pmc/articles/PMC9842514/ /pubmed/36660558 http://dx.doi.org/10.2147/JPR.S387548 Text en © 2023 Chen and Luo. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Chen, Xingchen
Luo, Yujia
Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era
title Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era
title_full Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era
title_fullStr Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era
title_full_unstemmed Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era
title_short Digital Therapeutics in Migraine Management: A Novel Treatment Option in the COVID-19 Era
title_sort digital therapeutics in migraine management: a novel treatment option in the covid-19 era
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842514/
https://www.ncbi.nlm.nih.gov/pubmed/36660558
http://dx.doi.org/10.2147/JPR.S387548
work_keys_str_mv AT chenxingchen digitaltherapeuticsinmigrainemanagementanoveltreatmentoptioninthecovid19era
AT luoyujia digitaltherapeuticsinmigrainemanagementanoveltreatmentoptioninthecovid19era